Source comparison
BPC-157 Research Recovery: Recovery Model Comparison
Achilles Tendon Transection 200–500 mcg/kg BID Subcutaneous (peri-lesional) 14–28 days Collagen fiber alignment, tensile strength Doses above 500 mcg/kg show no additional benefit—250 mcg/kg BID is the validated sweet spot for rodent tendon models Muscle Crush
This comparison does not assign a generated winner or score.
- Achilles Tendon Transection
- 200–500 mcg/kg BID
- Subcutaneous (peri-lesional)
- 14–28 days
- Collagen fiber alignment, tensile strength
- Doses above 500 mcg/kg show no additional benefit—250 mcg/kg BID is the validated sweet spot for rodent tendon models
- Muscle Crush Injury
- 200–400 mcg/kg BID
- Subcutaneous (injury site)
- 7–14 days
- Myofiber regeneration, creatine kinase levels
- Early-phase dosing (day 3–14) outperforms immediate post-injury administration
- Gastric Ulcer
- 10 mcg/kg (injectable) or 50–100 mcg/kg (oral)
- Intraperitoneal or oral
- Ulcer area reduction, mucosal healing
- Oral route requires 5–10× higher doses due to low bioavailability but avoids injection stress in GI models
- Ligament Injury (MCL)
- 21–28 days
- Histological healing score, biomechanical strength
- Longer treatment windows (21–28 days) required for ligament vs tendon due to lower vascular density
- Bone Fracture
- 10–20 mcg/kg QD
- Intraperitoneal
- 14–21 days
- Callus formation, radiographic union
- Lower doses effective in fracture models—mechanism involves angiogenesis support rather than direct osteoblast stimulation
- This table represents published dose ranges that produced statistically significant outcomes in peer-reviewed preclinical studies. Doses below these thresholds consistently fail to reach significance. Doses above the upper ranges show plateau effects without proportional benefit.